熱門資訊> 正文
Tectontic获得FDA批准开始对先导药物TX45进行临床测试
2024-07-31 06:54
- Tectonic Therapeutics (NASDAQ:TECX) said it has received FDA clearance for its Investigational New Drug application for TX45 for the treatment of a type of pulmonary hypertension.
- The company said it intends to initiate a Phase 2 study of the drug in Q3 for the treatment of patients with Group 2 pulmonary hypertension due to heart failure with preserved ejection fraction. Topline results are anticipated in 2026, according to a statement.
- Tectonic added that topline results from a Phase 1a study of TX45 are expected to be released in September, while topline results from a Phase 1b study are anticipated in mid-2025.
- Tectonic merged with AVROBIO in June.
More on AVROBIO
- Tectonic, AVROBIO complete merger, announce $130.7M private placement
- Historical earnings data for AVROBIO
- Financial information for AVROBIO
推薦文章
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
華盛早報丨重大突破！三大加密貨幣法案眾議院闖關成功；美聯儲，降息大消息
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
